Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E−/− mice

British Journal of Pharmacology

Volumn 174, Issue 22, 2017, Pages 4043-4054

  Petri, Marcelo H ^a   Laguna Fernandez, Andrés ^a   Arnardottir, Hildur ^a   Wheelock, Craig E ^a   Perretti, Mauro ^b   Hansson, Göran K ^a   Bäck, Magnus ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN E; ASPIRIN TRIGGERED LIPOXIN A4; CHEMOKINE; CYTOKINE; LIPID; LIPOXIN A; MESSENGER RNA; UNCLASSIFIED DRUG; FORMYL PEPTIDE RECEPTOR 2, MOUSE; FORMYLPEPTIDE RECEPTOR; LIPOXIN;

ABDOMINAL AORTA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTIC ROOT; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEART PROTECTION; LEUKOCYTE COUNT; LIPID DIET; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; THORACIC AORTA; ANIMAL; AORTA; DRUG EFFECT; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY;

ANIMALS; AORTA; APOLIPOPROTEINS E; ASPIRIN; ATHEROSCLEROSIS; CYTOKINES; FEMALE; LIPOXINS; MICE, KNOCKOUT; RECEPTORS, FORMYL PEPTIDE;

EID: 85013054716     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13707     Document Type: Article

References (36)

1. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015). The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 172: 5744–5869.
2. Bäck M, Hansson GK (2015). Anti-inflammatory therapies for atherosclerosis. Nat Rev Cardiol 12: 199–211.
3. Bäck M, Bu DX, Branstrom R, Sheikine Y, Yan ZQ, Hansson GK (2005). Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci U S A 102: 17501–17506.
4. Bäck M, Powell WS, Dahlen SE, Drazen JM, Evans JF, Serhan CN et al. (2014). Update on leukotriene, lipoxin and oxoeicosanoid receptors: IUPHAR Review 7. Br J Pharmacol 171: 3551–3574.
5. Barnig C, Cernadas M, Dutile S, Liu X, Perrella MA, Kazani S et al. (2013). Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci Transl Med 5.174ra126
6. Brancaleone V, Gobbetti T, Cenac N, le Faouder P, Colom B, Flower RJ et al. (2013). A vasculo-protective circuit centered on lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 operative in murine microcirculation. Blood 122: 608–617.
7. Brezinski DA, Nesto RW, Serhan CN (1992). Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy. Circulation 86: 56–63.
8. Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN (2014). Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am J Physiol Cell Physiol 307: C39–C54.
9. Curtis MJ, Bond RA, Spina D, Ahluwalia A, Alexander SP, Giembycz MA et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br J Pharmacol 172: 3461–3471.
10. Devchand PR, Arita M, Hong S, Bannenberg G, Moussignac RL, Gronert K et al. (2003). Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host defense. FASEB J 17: 652–659.
11. Drechsler M, de Jong R, Rossaint J, Viola JR, Leoni G, Wang JM et al. (2015). Annexin A1 counteracts chemokine-induced arterial myeloid cell recruitment. Circ Res 116: 827–835.
12. Dufton N, Hannon R, Brancaleone V, Dalli J, Patel HB, Gray M et al. (2010). Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol 184: 2611–2619.
13. Fredman G, Kamaly N, Spolitu S, Milton J, Ghorpade D, Chiasson R et al. (2015). Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med 7.275ra220
14. Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR (2000). Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 164: 1663–1667.
15. Hayhoe RP, Kamal AM, Solito E, Flower RJ, Cooper D, Perretti M (2006). Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. Blood 107: 2123–2130.
16. Ho KJ, Spite M, Owens CD, Lancero H, Kroemer AH, Pande R et al. (2010). Aspirin-triggered lipoxin and resolvin E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol 177: 2116–2123.
17. Ingelsson E, Yin L, Back M (2012). Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol 129: 702–707.e702
18. Ketelhuth DF, Hermansson A, Hlawaty H, Letourneur D, Yan ZQ, & Back M (2015). The leukotriene B receptor (BLT) antagonist BIIL284 decreases atherosclerosis in ApoE mice. Prostaglandins & other lipid mediators.
19. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.
20. Krishnamoorthy S, Recchiuti A, Chiang N, Fredman G, Serhan CN (2012). Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol 180: 2018–2027.
21. Libby P, Ridker PM, Hansson GK (2011). Progress and challenges in translating the biology of atherosclerosis. Nature 473: 317–325.
22. Maderna P, Cottell DC, Toivonen T, Dufton N, Dalli J, Perretti M et al. (2010). FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin-derived peptide-stimulated phagocytosis. FASEB J 24: 4240–4249.
23. McGrath JC, Lilley E (2015). Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 172: 3189–3193.
24. Petri MH, Laguna-Fernandez A, Gonzalez-Diez M, Paulsson-Berne G, Hansson GK, Bäck M (2015a). The role of the FPR2/ALX receptor in atherosclerosis development and plaque stability. Cardiovasc Res 105: 65–74.
25. Petri MH, Laguna-Fernandez A, Tseng CN, Hedin U, Perretti M, Bäck M (2015b). Aspirin-triggered 15-epi-lipoxin A(4) signals through FPR2/ALX in vascular smooth muscle cells and protects against intimal hyperplasia after carotid ligation. Int J Cardiol 179: 370–372.
26. Serhan CN (1997). Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): a jungle of cell–cell interactions or a therapeutic opportunity? Prostaglandins 53: 107–137.
27. Serhan CN (2014). Pro-resolving lipid mediators are leads for resolution physiology. Nature 510: 92–101.
28. Smith HK, Gil CD, Oliani SM, Gavins FN (2015). Targeting formyl peptide receptor 2 reduces leukocyte-endothelial interactions in a murine model of stroke. FASEB J 29: 2161–2171.
29. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 44: D1054–D1068.
30. Stanke-Labesque F, Pepin JL, de Jouvencel T, Arnaud C, Baguet JP, Petri MH et al. (2012). Leukotriene B4 pathway activation and atherosclerosis in obstructive sleep apnea. J Lipid Res 53: 1944–1951.
31. −/− mice. Arterioscler Thromb Vasc Biol 28: 1421–1428.
32. van Gils JM, Derby MC, Fernandes LR, Ramkhelawon B, Ray TD, Rayner KJ et al. (2012). The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques. Nat Immunol 13: 136–143.
33. Van Vre EA, Ait-Oufella H, Tedgui A, Mallat Z (2012). Apoptotic cell death and efferocytosis in atherosclerosis. Arterioscler Thromb Vasc Biol 32: 887–893.
34. Vital SA, Becker F, Holloway PM, Russell J, Perretti M, Granger DN et al. (2016). Formyl-peptide receptor 2/3/lipoxin A4 receptor regulates neutrophil–platelet aggregation and attenuates cerebral inflammation: impact for therapy in cardiovascular disease. Circulation 133: 2169–2179.
35. Wu J, Wang A, Min Z, Xiong Y, Yan Q, Zhang J et al. (2011). Lipoxin A4 inhibits the production of proinflammatory cytokines induced by beta-amyloid in vitro and in vivo. Biochem Biophys Res Commun 408: 382–387.
36. Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M et al. (2009). International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev 61: 119–161.